Physician profile
Divya Arora
NPI 1891053757
$332.95
in general payments reported to CMS, 2019-2025
13 companies · $22.79 in 2025
The $22.79 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $34.18 · 2021: $74.32 · 2022: $19.04 · 2025: $22.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $53.42 | 2019-2020 | |
| Myovant Sciences INC. | $52.82 | 2021 | |
| Genzyme Corporation | $34.91 | 2019 | |
| Janssen Biotech, INC. | $27.84 | 2019 | |
| Celgene Corporation | $27.63 | 2019 | |
| Amgen INC. | $23.57 | 2019 | |
| Novocure INC. | $22.79 | 2025 | Optune Gio |
| Coherus Oncology, INC. | $21.50 | 2021 | |
| Siemens Medical Solutions USA, INC. | $19.04 | 2022 | |
| Boston Scientific Corporation | $14.92 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.56 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $11.52 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divya Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.